Introduction
Prosthetic joint infection (PJI) is a serious complication of arthroplasty that is difficult to cure, is associated with prolonged hospital stay and has significant costs 1 . The optimal treatment approach remains contentious. Traditionally treatment has been with one-or two-stage prosthesis exchange, which has resulted in high rates of success in treating infection but given the technically difficult and extensive surgery required, likely involves significant morbidity 2 . There is growing evidence demonstrating successful treatment of early PJI with surgical debridement, retention of prosthesis and the use of biofilm-active antibiotics such as rifampicin for staphylococcal infections and fluoroquinolones for gram-negative infections 3 . This approach has been favoured more recently as it involves less extensive surgery than prosthesis exchange and so ostensibly results in better function, quality of life(QOL) and less morbidity, however few studies have formally assessed these outcomes. Our aim was therefore to describe rates of successful infection treatment for patients undergoing treatment for PJI with surgical debridement, prosthesis retention and biofilm-active antibiotics and compare their functional outcomes, QOL and complication rates to patients without PJI.
Methods
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Study Design
This was a case-control study performed at a single tertiary institution, St Vincent's Hospital in Melbourne, Australia(SVHM).
Study population
Cases and controls were identified from an arthroplasty registry that was prospectively compiled by a single researcher on consecutive patients undergoing primary hip arthoplasty at SVHM between January 2006 and December 2009. The registry, previously described 4 , actively collected information on basic demographics, comorbidities, type of surgery, complications (including the presence of PJI) and pre-and 12-month post-procedure functional and QOL assessments. The Charlson comorbidity index (CCI), a score of comorbidities that includes age 5 , was calculated pre-operatively.
Over the study period 981 hip arthroplasty operations were performed and minimum 12-month follow-up information was available on 952, with the remaining 39 unavailable because of death from causes unrelated to surgery (13 patients) or loss to follow-up (16 patients).
Eligible cases were patients who developed PJI some time prior to the 12-month post-arthroplasty assessment and had treatment with prosthesis debridement and retention. Patients were excluded if the infected prosthesis was a megaprosthesis for bone tumour surgery or if the primary surgical treatment was prosthesis removal or revision. Controls were patients who did not develop PJI within 12 Accepted Article 4 months from arthroplasty and were matched at a ratio of 4 to 1 to cases by age and pre-arthroplasty Harris Hip Score 6 .
During the study period a protocol existed where early PJI (<3 months from implantation) 2 or haematogenous PJI was treated with retention of the prosthesis and prompt, aggressive, repeated, open surgical debridement involving removal of infected soft tissue, large volume high-pressure lavage, and change of polyethylene liner at the last debridement operation. After an initial short period of intravenous antibiotics (10-14 days) patients were treated with oral antibiotic combinations depending on organism sensitivities and with preference given to agents with activity against biofilm-associated bacteria such as rifampicin, fusidic acid and/or ciprofloxacin 7 .
PJI and infection outcome definitions
The presence of a prosthetic joint infection was defined as per the USA CDC definition of deep organ/space surgical site infection 8 . All microbiology cultures results were considered significant if the same microorganism/s were isolated on two or more intra-operative specimens 9 .
Treatment failure was defined as persistence or recurrence of symptoms or signs of prosthetic infection, the isolation of the same or different organisms from subsequent operative samples, the removal of the prosthesis while antibiotic therapy continued or death from PJI.
Functional and Quality of life assessments
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Functional assessments were performed using the Harris Hip Score (HHS), a disease specific scoring system that assesses hip pain, function, range of motion and deformity 6, 10 . The maximum HHS is 100 and outcomes have been interpreted as: 100-90=excellent; 89-80=good; 79-70=fair; <70=poor 11 . An adverse functional outcome in this study was defined as a HHS < 70, equating to a poor result. QOL and general health was assessed using the 12-item Short Form Health Survey (SF- 
Results
Accepted Article
7
Over the study period there were a total of 21 PJI identified. One patient was excluded from further examination as they underwent primary prosthesis resection and another was excluded because they underwent 2-stage prosthesis exchange. The remaining 19 cases were managed by debridement and prosthesis retention. Baseline demographic information of cases and controls is shown in Table 1 . For cases, the median duration from joint insertion until first debridement (joint age) was 14 days (IQR 12-20). The median duration of symptoms until debridement was 4 days (IQR 3-9). The median duration of follow-up for cases from the time of infection was 24 months (IQR 15-37).
Microbiology
Eleven of the PJI cases were polymicrobial, 7 were monomicrobial and 1 was culture negative. Staphylococcus aureus was isolated in 9 cases (3 of these methicillin-resistant), coagulase-negative staphylococci in 10, gram-negative bacilli in 7 and enterococci in 6. The microbiology of individual cases is shown in Table 2 .
Surgical treatment
The median number of debridement operations per case patient was 3 (range 3 to p=0.34). Results from multivariate logistic regression analysis can be seen in Table   4 . From multivariate analysis, predictors of an adverse HHS outcome were higher BMI and age-adjusted Charlson co-morbidity index. Predictors of an adverse SF-12 PCS outcome were being female and a higher age-adjusted Charlson co-morbidity index. Higher pre-operative PCS and MCS scores were protective against adverse PCS and MCS outcomes respectively.
Complications
The majority of complications were medical and were made up of drug reactions, delerium, venous thromboembolism, cardiac arrhythmias and pneumonia. Cases Accepted Article (6/ 
Discussion
The treatment of PJI with debridement, retention of prosthesis and biofilm-active antibiotics in our cohort was successful, with only 2 of 19 patients showing evidence of infection relapse over a median duration of follow-up of 24 months and an 88% survival free from treatment failure at 2 years. Early studies examining outcomes of PJI treatment with prosthesis retention had poor outcomes, with success rates of <70% 14 . More recent studies, where patients mainly with early PJI were included and where antibiotic treatment was with biofilm-active antibiotic combinations, especially rifampicin, have reported good outcomes similar to our study. These results are comparable to treatment with 1 or 2-stage prosthesis exchange, approaches traditionally regarded as superior to prosthesis retention in successfully eradicating PJI but which involve more extensive surgery 14 . Given that results for successful infection eradication for these different management approaches appear to be similar in appropriately selected patients, it is important to consider other issues that may influence treatment decisions such as functional outcomes, QOL and treatment-associated Accepted Article complications, which have been infrequently reported previously in studies examining PJI management.
Despite having a PJI, cases in this study treated with debridement and retention of prosthesis had a significant improvement from pre-arthroplasty to 12-months post-arthroplasty in functional outcome according to HHS (+35.9; p<0.001). This improvement was not significantly different to that seen in control patients with no PJI and is similar to results of +33 and +39.1 reported in 2 previous studies examining treatment of PJI with mainly prosthesis exchange 15, 16 . Other studies have reported mean post-treatment HHS after treatment of PJI with prosthesis exchange at between 69 and 84 17 and after debridement and prosthesis retention at 79 9 . The mean post-arthroplasty HHS of 68.5 seen in cases in this study is at the lower end of these scores, however adequate comparison is difficult as these studies do not report pre-arthroplasty HHS and administered the score much later than in this study.
There was improvement for cases in this study in QOL outcomes according to SF-12 PCS score from pre-arthroplasty to 12-months post-arthroplasty of +10.9(p<0.001) and this was not significantly different to controls. The 12-month mean SF-12 PCS score of 33.7 for cases is similar to that reported in 1 previous study examining outcomes after treatment with 2 stage-exchange 18 .
There was no improvement between pre-arthroplasty and post-arthroplasty SF-12 MCS score for either cases or controls and no differences between the groups, Medical complications occurred more commonly in patients with PJI compared with controls in this study but these were mainly drug reactions to intravenous or oral antibiotics to which controls were obviously not exposed. Rates of other medical or surgical complications occurred at similar rates in cases and controls despite the extra surgical and medical treatment required for PJI cases, suggesting that, aside from the risk of drug reaction, this treatment approach is well tolerated.
Very few previous studies examining PJI outcomes report treatment complication rates however 1 study reported a high rate of 58 complications occurring in 68 patients treated with prosthesis exchange 17 .
It is important to note that the results of the present study cannot be generalised to all prosthetic joint infections treated with debridement and retention. Each case patient in the study exhibited features that have been shown previously to be associated with good treatment success rates. In particular, they were all early PJI, with a short joint age (14 days) and short duration of symptoms (4 days) until initial debridement 2 . These factors may also be associated with better function and QOL and less complications, however this association is yet to be studied.
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The retrospective design of this study is an obvious limitation given the risk of incomplete or variably recorded information, especially the occurrence of complications. However the prospective collection of data by a single researcher and using standard definitions minimised biases arising from this. The relatively small sample size in this study means it was not powered to detect smaller differences in outcomes or infrequently occurring risk factors for poor outcomes.
This study suggests that patients treated for early PJI with debridement, prosthesis retention and biofilm-active antibiotics results in not only successful treatment of infection but also significant improvements in functional and QOL outcomes, which are similar to patients without PJI. Treatment is well tolerated however is associated with the risk of drug reaction. Given the good results in successful PJI treatment obtained from both debridement and retention as well as prosthesis exchange, future studies are required directly comparing these approaches and should include functional outcomes, QOL outcomes and complication rates to better inform management decisions. 
